Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Third-quarter 2009 results announced by Response Biomedical

Third-quarter 2009 results announced by Response Biomedical

Third quarter 2009 financial results announced by Aradigm

Third quarter 2009 financial results announced by Aradigm

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

NanoLogix files international patent applications for its BioNanoPore microorganism detecting technology

NanoLogix files international patent applications for its BioNanoPore microorganism detecting technology

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

NIH awards contract to LRRI for anthrax research

NIH awards contract to LRRI for anthrax research

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene to acquire U.S. commercialization rights for HepaGam B

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Roundtable discussion to elevate awareness about the importance of biopreparedness

Roundtable discussion to elevate awareness about the importance of biopreparedness

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.